Multiple myeloma, aka Kahler’s disease, is a cancer that forms in a type of white blood cell called a plasma cell, and inhibits their ability to fight infection. The American Cancer Society estimates it causes more than 12,400 deaths in the U.S. each year. Prior to this week, there was only one therapy available, which caused supply issues. A recent article from The Wall Street Journal discussed the FDA’s approval of a second CAR-T cancer therapy to treat multiple myeloma.
FDA Approves New CAR-T Therapy for Multiple Myeloma
The approval could open the door to more Western pharmaceutical companies looking to bring China-developed therapies to the U.S.
Mar 2, 2022
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
